Immune Therapeutics Correlations
A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Immune |
The ability to find closely correlated positions to Immune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immune Therapeutics to buy it.
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Immune Pink Sheet performing well and Immune Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Immune Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RSPI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BIEI | 6.82 | (0.52) | 0.00 | 1.41 | 0.00 | 16.67 | 47.62 | |||
| USRM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| NPHC | 2.98 | 1.50 | 0.00 | 8.60 | 0.00 | 0.00 | 0.00 | |||
| MYMX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Immune Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immune Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Immune Therapeutics could also be used in its relative valuation, which is a method of valuing Immune Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Immune Therapeutics Corporate Management
| Joseph Fortunak | VP of Global RandD and Chemical Devel. and Member of Advisory Board | Profile | |
| Glen MBA | Chief Officer | Profile | |
| FMedSci FRACP | Chief RD | Profile | |
| Kelly Wilson | Interim Pres | Profile |
Still Interested in Immune Therapeutics?
Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.